{
    "text_blocks": {
        "data": {
            "block_count": 9,
            "table_index": 1
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1",
                    "1": "1",
                    "2": "1"
                },
                "decision": "1"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-01-21_09-37-36"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tSeptember 30, 2021\tDecember 31, 2020\t",
        "timestamp": "2025-03-11_12-28-50"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-28-53"
    },
    "post_table_text": {
        "data": "\tSee accompanying notes.\t2\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS O",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tSee accompanying notes.\t2\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS O'"
                },
                "decision": "'\tSee accompanying notes.\t2\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS O'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-28-55"
    },
    "table_body": {
        "data": "Assets\tCurrent assets:\tCash and cash equivalents\t$\t4,362\t$\t5,997\tShort-term marketable securities\t1,376\t1,411\tAccounts receivable, net\t4,566\t4,892\tInventories\t1,676\t1,683\tPrepaid and other current assets\t2,011\t2,013\tTotal current assets\t13,991\t15,996\tProperty, plant and equipment, net\t5,037\t4,967\tLong-term marketable securities\t1,099\t502\tIntangible assets, net\t33,900\t33,126\tGoodwill\t8,332\t8,108\tOther long-term assets\t4,739\t5,708\tTotal assets\t$\t67,098\t$\t68,407\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t585\t$\t844\tAccrued government and other rebates\t3,368\t3,460\tAccrued and other current liabilities\t3,781\t4,336\tCurrent portion of long-term debt and other obligations, net\t2,511\t2,757\tTotal current liabilities\t10,245\t11,397\tLong-term debt, net\t25,175\t28,645\tLong-term income taxes payable\t4,642\t5,016\tDeferred tax liability\t4,603\t3,914\tOther long-term obligations\t962\t1,214\tCommitments and contingencies (Note 11)\tStockholders  equity:\tPreferred stock, par value $\t0.001\tper share;\t5\tshares authorized;\tno\tne outstanding\t \t \tCommon stock, par value $\t0.001\tper share;\t5,600\tshares authorized;\t1,255\tand\t1,254\tshares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t4,492\t3,880\tAccumulated other comprehensive income (loss)\t74\t(\t60\t)\tRetained earnings\t16,903\t14,381\tTotal Gilead stockholders  equity\t21,470\t18,202\tNoncontrolling interest\t1\t19\tTotal stockholders  equity\t21,471\t18,221\tTotal liabilities and stockholders  equity\t$\t67,098\t$\t68,407",
        "timestamp": "2025-03-11_12-28-55"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [4362, 5997], \"Short-term marketable securities\": [1376, 1411], \"Accounts receivable, net\": [4566, 4892], \"Inventories\": [1676, 1683], \"Prepaid and other current assets\": [2011, 2013], \"Total current assets\": [13991, 15996]}, \"Property, plant and equipment, net\": [5037, 4967], \"Long-term marketable securities\": [1099, 502], \"Intangible assets, net\": [33900, 33126], \"Goodwill\": [8332, 8108], \"Other long-term assets\": [4739, 5708], \"Total assets\": [67098, 68407]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [585, 844], \"Accrued government and other rebates\": [3368, 3460], \"Accrued and other current liabilities\": [3781, 4336], \"Current portion of long-term debt and other obligations, net\": [2511, 2757], \"Total current liabilities\": [10245, 11397]}, \"Long-term debt, net\": [25175, 28645], \"Long-term income taxes payable\": [4642, 5016], \"Deferred tax liability\": [4603, 3914], \"Other long-term obligations\": [962, 1214], \"Commitments and contingencies\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no one outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [4492, 3880], \"Accumulated other comprehensive income (loss)\": [74, -60], \"Retained earnings\": [16903, 14381], \"Total Gilead stockholders equity\": [21470, 18202], \"Noncontrolling interest\": [1, 19], \"Total stockholders equity\": [21471, 18221]}, \"Total liabilities and stockholders equity\": [67098, 68407]}}"
                },
                "decision": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [4362, 5997], \"Short-term marketable securities\": [1376, 1411], \"Accounts receivable, net\": [4566, 4892], \"Inventories\": [1676, 1683], \"Prepaid and other current assets\": [2011, 2013], \"Total current assets\": [13991, 15996]}, \"Property, plant and equipment, net\": [5037, 4967], \"Long-term marketable securities\": [1099, 502], \"Intangible assets, net\": [33900, 33126], \"Goodwill\": [8332, 8108], \"Other long-term assets\": [4739, 5708], \"Total assets\": [67098, 68407]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [585, 844], \"Accrued government and other rebates\": [3368, 3460], \"Accrued and other current liabilities\": [3781, 4336], \"Current portion of long-term debt and other obligations, net\": [2511, 2757], \"Total current liabilities\": [10245, 11397]}, \"Long-term debt, net\": [25175, 28645], \"Long-term income taxes payable\": [4642, 5016], \"Deferred tax liability\": [4603, 3914], \"Other long-term obligations\": [962, 1214], \"Commitments and contingencies\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no one outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 shares authorized; 1,255 and 1,254 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [4492, 3880], \"Accumulated other comprehensive income (loss)\": [74, -60], \"Retained earnings\": [16903, 14381], \"Total Gilead stockholders equity\": [21470, 18202], \"Noncontrolling interest\": [1, 19], \"Total stockholders equity\": [21471, 18221]}, \"Total liabilities and stockholders equity\": [67098, 68407]}}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-30-42"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-30-42"
    }
}